Ancient Adaptogen: Fulvic Acid and Mineral Pitch

Evidence Review

Testosterone and Fertility (Human RCTs)

The most robust human evidence for shilajit centers on androgen effects. Biswas et al. (2010) enrolled 35 men with oligospermia in an open-label trial using 100 mg processed shilajit twice daily for 90 days [1]. Of 28 completers, total sperm count rose by 61.4% (from a mean of ~13.8 to ~22.3 million/mL), total motility by 17.4% for fast progressive sperm, and normal sperm morphology by 18.9%. Total testosterone increased 23.5% (p < 0.001) and FSH rose 9.4% (p < 0.05), with no adverse changes in liver or kidney function markers. Limitations include lack of placebo control and small sample size.

Pandit et al. (2016) addressed the placebo control gap with a randomized, double-blind, placebo-controlled trial in 96 healthy men aged 45–55 [2]. At 250 mg twice daily for 90 days, the treatment group showed statistically significant increases in total testosterone (p < 0.05), free testosterone (p < 0.05), and DHEAS (p < 0.05) compared to placebo. Gonadotropins (LH, FSH) were unchanged, suggesting the mechanism is not through increased luteinizing hormone signaling but likely through enhanced testicular steroidogenesis or reduced metabolic conversion. This study provides the strongest evidence for shilajit's testosterone effects in the general male population.

Physical Performance (Human RCT)

Keller et al. (2019) conducted an 8-week parallel-group RCT in 63 recreationally active men randomized to placebo, 250 mg/day, or 500 mg/day of PrimaVie® shilajit [3]. The primary outcome was maximal voluntary isometric contraction force before and after a fatiguing protocol. The 500 mg group showed significantly less post-fatigue strength decline: 8.9 ± 2.3% vs. 16.0 ± 2.4% in placebo (p = 0.044) and 17.0 ± 2.4% in the 250 mg group (p = 0.022). Serum hydroxyproline — a byproduct of collagen breakdown reflecting connective tissue stress — was also significantly lower in the 500 mg group: 1.5 ± 0.3 μg/mL vs. 2.4 ± 0.3 μg/mL in placebo (p = 0.024). The 250 mg dose did not differ from placebo on either measure, suggesting a dose-dependent effect.

Skeletal Muscle Gene Expression (Human Clinical)

Das et al. (2016) examined transcriptomic changes in skeletal muscle biopsies from overweight/obese adults given 250 mg PrimaVie® twice daily for 8 weeks [6]. RNA microarray analysis revealed upregulation of 17 extracellular matrix gene probe sets, including collagen types I, III, V, VI, and XIV at 4.61–5.18-fold increases, fibronectin 1 at 3.65-fold, fibrillin 1 at 3.05-fold, and decorin at 2.23-fold. These structural proteins support the mechanical integrity of muscle fibers and their attachment to connective tissue. No adverse changes in blood glucose, lipids, creatine kinase, or serum myoglobin were observed. The study was not powered to detect functional performance outcomes, so the mechanistic findings need to be linked to performance studies (such as Keller et al.) for clinical interpretation.

Mitochondrial and Fatigue Mechanisms (Animal)

Surapaneni et al. (2012) modeled chronic fatigue syndrome in rats via 21 days of forced swimming, then treated with shilajit at 25, 50, and 100 mg/kg [5]. Shilajit reversed CFS-induced behavioral symptoms (immobility, anxiety), normalized plasma corticosterone and adrenal gland weight indicating HPA axis restoration, and preserved mitochondrial membrane potential and electron transport chain complex activities. Nitric oxide and lipid peroxidation markers were also reduced. The shilajit used was standardized to 0.43% DBPs, 20.45% DBP-chromoproteins, and 56.75% fulvic acids. These animal findings are mechanistically consistent with the human fatigue and performance data but cannot be directly extrapolated to humans.

Cognitive and Neuroprotective Effects (In Vitro and Review)

Carrasco-Gallardo et al. (2012) reviewed the biological basis for shilajit's potential in cognitive aging [4]. Fulvic acid was shown to inhibit tau self-aggregation in vitro and to disaggregate pre-formed tau filaments — both key mechanisms in Alzheimer's pathology. The authors also cite fulvic acid's antioxidant capacity, its ability to reduce amyloid-beta aggregation, and its anti-inflammatory profile as supportive evidence. The study is a narrative review with in vitro data, not a clinical trial, and the translation from cell culture to human benefit requires further clinical investigation.

Safety Profile

Stohs (2014) reviewed the available safety and efficacy data across animal and human studies [7]. Across multiple human trials, shilajit at doses of 100–500 mg/day showed no adverse effects on liver enzymes, kidney function, blood cell counts, blood glucose, or lipid panels. The review confirmed the primary active compounds as DBPs, fulvic acid, and their derivatives, and characterized the overall evidence as promising but in need of larger, longer-duration clinical trials.

Overall Assessment

The human evidence for testosterone support is the strongest, with two controlled trials showing consistent effects. Physical performance evidence is supported by one solid RCT. Cognitive protection remains largely preclinical. The primary limitation across the literature is study size — most human trials involve fewer than 100 participants. Bioavailability is also rarely standardized across trials, making dose comparisons difficult. The safety profile is reassuring across all available data, and the compound's multi-target profile (hormonal, mitochondrial, structural, cognitive) is mechanistically coherent with its chemical composition.